NSAIDs in combination therapy for the treatment of chronic pseudophakic cystoid macular edema

Retina

Volumn 30, Issue 2, 2010, Pages 260-266

  Warren, Keith A ^a,b   Bahrani, Hasan ^a   Fox, Jenni E ^a  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^b Warren Retina Associates   (United States)

Author keywords

Bevacizumab; Bromfenac; Corticosteroids; Cystoid macular edema; Diclofenac; Ketorolac; Nepafenac; Nonsteroidal antiinflammatory drugs; Pseudophakic; Triamcinolone

Indexed keywords

BEVACIZUMAB; BROMFENAC; DICLOFENAC; KETOROLAC; KETOROLAC TROMETAMOL; NEPAFENAC; PLACEBO; TRIAMCINOLONE;

ABSENCE OF SIDE EFFECTS; ADULT; AGE DISTRIBUTION; AGED; ANTIANGIOGENIC THERAPY; ARTICLE; CHRONIC DISEASE; CHRONIC PSEUDOPHAKIC CYSTOID MACULAR EDEMA; CLINICAL ARTICLE; CLINICAL TRIAL; CONJUNCTIVITIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DISEASE DURATION; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; FEMALE; HUMAN; INTRAOCULAR FOREIGN BODY; INTRAOCULAR PRESSURE; MALE; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIAL; RETINA MACULA CYSTOID EDEMA; SEX DIFFERENCE; SIDE EFFECT; SINGLE BLIND PROCEDURE; THICKNESS; VISUAL ACUITY;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; BENZENEACETAMIDES; BENZOPHENONES; BROMOBENZENES; DICLOFENAC; DRUG THERAPY, COMBINATION; FEMALE; FLUORESCEIN ANGIOGRAPHY; GLUCOCORTICOIDS; HUMANS; INJECTIONS; KETOROLAC; MACULAR EDEMA; MALE; MIDDLE AGED; PHENYLACETATES; PSEUDOPHAKIA; RETINA; SINGLE-BLIND METHOD; TREATMENT OUTCOME; TRIAMCINOLONE ACETONIDE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; VITREOUS BODY;

EID: 76749101160     PISSN: 0275004X     EISSN: None     Source Type: Journal    
DOI: 10.1097/IAE.0b013e3181b8628e     Document Type: Article

References (27)

1. Drolsum L, Haaskjold E. Causes of decreased visual acuity after cataract extraction. J Cataract Refract Surg 1995;21: 59-63.
2. Henderson BA, Kim JY, Ament CS, Ferrufino-Ponce ZK, Grabowska A, Cremers SL. Clinical pseudophakic cystoid macular edema. Risk factors for development and duration after treatment. J Cataract Refract Surg 2007;33:1550-1558.
3. Rothova A. Inflammatory cystoid macular edema. Curr Opin Ophthalmol 2007;18:487-492.
4. Tranos PG, Wickremasinghe SS, Stangos NT, Topouzis F, Tsinopoulos I, Pavesio CE. Macular edema. Surv Ophthalmol 2004;49:470-490.
5. Flower RJ. Studies on the mechanism of action of anti-inflammatory drugs. A paper in honour of John Vane. Thromb Res 2003;110:259-263.
6. O'Brien TP. Emerging guidelines for use of NSAID therapy to optimize cataract surgery patient care. Curr Med Res Opin 2005;21:1131-1137.
7. Edelman JL, Lutz D, Castro MR. Corticosteroids inhibit VEGF-induced vascular leakage in a rabbit model of bloodretinal and blood-aqueous barrier breakdown. Exp Eye Res 2005;80:249-258.
8. Ahmadieh H, Ramezani A, Shoeibi N, et al. Intravitreal bevacizumab with or without triamcinolone for refractory diabetic macular edema; a placebo-controlled, randomized clinical trial. Graefes Arch Clin Exp Ophthalmol 2008;246:483-489.
9. Grant C. Combination therapy: lucentis (ranibizumab injection) and xibrom (bromfenac ophthalmic solution) 0.09% in the treatment of choroidal neovascular membrane secondary to age-related macular degeneration. Invest Ophthalmol Vis Sci 2008;49:E-Abstract 563.
10. Heier JS, Topping TM, Baumann W, Dirks MS, Chern S. Ketorolac versus prednisolone versus combination therapy in the treatment of acute pseudophakic cystoid macular edema. Ophthalmology 2000;107:2034 -2038; discussion 2039.
11. Levin DS, Lim JI. Update on pseudophakic cystoid macular edema treatment options. Ophthalmol Clin North Am 2002; 15:467-472.
12. Arevalo JF, Garcia-Amaris RA, Roca JA, et al; Pan-American Collaborative Retina Study Group. Primary intravitreal bevacizumab for the management of pseudophakic cystoid macular edema: pilot study of the Pan-American Collaborative Retina Study Group. J Cataract Refract Surg 2007;33:2098-2105.
13. Ostrov CS, Sirkin SR, Deutsch WE, Masi RJ, Chandler JW, Lindquist TD. Ketorolac, prednisolone, and dexamethasone for postoperative inflammation. Clin Ther 1997;19:259-272.
14. Bodaghi B, Weber ME, Arnoux YV, Jaulerry SD, Le Hoang P, Colin J. Comparison of the efficacy and safety of two formulations of diclofenac sodium 0.1% eyedrops in controlling postoperative inflammation after cataract surgery. Eur J Ophthalmol 2005;15:702-711.
15. Ke TL, Graff G, Spellman JM, Yanni JM. Nepafenac, a unique nonsteroidal prodrug with potential utility in the treatment of trauma-induced ocular inflammation: II. In vitro bioactivation and permeation of external ocular barriers. Inflammation 2000; 24:371-384.
16. Walters T, Raizman M, Ernest P, Gayton J, Lehmann R. In vivo pharmacokinetics and in vitro pharmacodynamics of nepafenac, amfenac, ketorolac, and bromfenac. J Cataract Refract Surg 2007;33:1539-1545.
17. Gamache DA, Graff G, Brady MT, Spellman JM, Yanni JM. Nepafenac, a unique nonsteroidal prodrug with potential utility in the treatment of trauma-induced ocular inflammation: I. Assessment of anti-inflammatory efficacy. Inflammation 2000; 24:357-370. (Pubitemid 30367882)
18. Kapin MA, Yanni JM, Brady MT, et al. Inflammation-mediated retinal edema in the rabbit is inhibited by topical nepafenac. Inflammation 2003;27:281-291.
19. Kern TS, Miller CM, Du Y, et al. Topical administration of nepafenac inhibits diabetes-induced retinal microvascular disease and underlying abnormalities of retinal metabolism and physiology. Diabetes 2007;56:373-379.
20. Dubois RN, Abramson SB, Crofford L, et al. Cyclooxygenase in biology and disease. FASEB J 1998;12:1063-1073.
21. Gulkilik G, Kocabora S, Taskapili M, Engin G. Cystoid macular edema after phacoemulsification: risk factors and effect on visual acuity. Can J Ophthalmol 2006;41:699-703.
22. Otani T, Kishi S. A controlled study of vitrectomy for diabetic macular edema. Am J Ophthalmol 2002;134:214-219. (Pubitemid 34831825)
23. Penn JS, Madan A, Caldwell RB, Bartoli M, Caldwell RW, Hartnett ME. Vascular endothelial growth factor in eye disease. Prog Retin Eye Res 2008;27:331-371.
24. Takahashi K, Saishin Y, Mori K, et al. Topical nepafenac inhibits ocular neovascularization. Invest Ophthalmol Vis Sci 2003;44:409-415.
25. Song Q, McCollum GW, Macrorie-Fairweather R, et al. Nepafenac metabolite, amfenac, inhibits VEGF induced phosphorylation of ERK in human retinal microvascular endothelial cells. Invest Ophthalmol Vis Sci 2005;46:E-Abstract 4204.
26. Sivaprasad S, McCluskey P, Lightman S. Intravitreal steroids in the management of macular oedema. Acta Ophthalmol Scand 2006;84:722-733.
27. Kim JE, Mantravadi AV, Hur EY, Covert DJ. Short-term intraocular pressure changes immediately after intravitreal injections of anti-vascular endothelial growth factor agents. Am J Ophthalmol 2008;146:930 -934.e1.